N/A N=10 Response Inhibition in Tourette Syndrome
Tourette Syndrome
Primary: Stop Signal Reaction Time (SSRT) — 249; 245 milliseconds — p=0.49
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=18 Ecopipam Treatment of Tourette Syndrome
Tourette's Syndrome
Primary: Yale Global Tic Severity Score — 25.3 units on a scale
Phase 2 N=40 Ecopipam Treatment of Tourette's Syndrome in Subjects 7-17 Years
Tourette's Syndrome
Primary: Yale Global Tic Severity Scale - Total Tic Score — -5.6; -3.4 Score on a scale — p=<0.05
N/A N=10 Transcranial Magnetic Stimulation for Children With Tourette's Syndrome
Tourette Syndrome
Primary: Yale Global Tic Severity Scale — 64.40; 26.40 units on a scale
Phase 2 N=20 Transcranial Magnetic Stimulation (TMS) for Individuals With Tourette's Syndrome
Tourette Syndrome
Primary: Yale Global Tic Severity Scale (Y-GTSS) — 29.5; 31.5 units on a scale
N/A N=10 Tourette Syndrome Deep Brain Stimulation
Tourette Syndrome
Primary: Number of Participants With a 40% Reduction in Total Tics on the Yale Global Tic Severity Scale (YGTSS) With CDBS (Period 1) — 4 Participants — p=0.05
N/A N=3 Combined CBIT and rTMS to Improve Tourette's Syndrome
Tourette Syndrome
Primary: Tic Severity — 59.3; 43.3; 37.67 score on a scale — p=0.1997
Phase 2 N=31 N-acetylcysteine (NAC) for Children With Tourette Syndrome
Tourettes Syndrome · Tic
Primary: Improvement in Tic Severity — 24.3; 21.3 units on a scale
N/A N=5 Brain Stimulation for the Treatment of Tourette Syndrome
Tourette Syndrome
Primary: Mean Change in Yale Global Tic Severity Scale (YGTSS) Scores From Baseline to 6 Months Across All Study Participants Presented — -20.33; -14.05; 91; 92.5 units on a…
Phase 3 N=29 A Randomized, Placebo-controlled, Tourette Syndrome Study.
Tourette Syndrome
Primary: Change From Baseline in Total Tic Score at Day 70 — -5.0; -14.29 units on a scale — p=0.0259
Phase 4 N=11 Open Label Trial of Aripiprazole in Children and Adolescents With Tourette's Disorder
Tourette's Syndrome · Tic Disorders
Primary: Calculating Difference Between Means (Baseline and Endpoint Scores on the Yale Global Tic Severity Scale Subscales) — 15.82; 9.73; 12.36; 7.00 units on a scale — p=<.05
Phase 2 N=124 Safety and Efficacy Study of NBI-98854 in Adults With Tourette Syndrome
Tourette Syndrome
Primary: Change From Baseline to Week 8 in the YGTSS TTS — -6.1; -7.4; -8.0 Least Squares Mean (Standard Error) — p=0.4326
Phase 3 N=119 Alternatives for Reducing Tics in Tourette Syndrome (TS): A Study of TEV-50717 (Deutetrabenazine) for the Treatment of Tourette Syndrome in Children and Adolescents
Tourette Syndrome
Primary: Change From Baseline in the TTS of the YGTSS at Week 12 — -9.1; -8.4 units on a scale — p=0.692
Phase 2 N=98 Safety and Efficacy Study of NBI-98854 in Children and Adolescents With Tourette Syndrome
Tourette Syndrome
Primary: Change From Baseline to Week 6 in the Yale Global Tic Severity Scale (YGTSS) Total Tic Score (TTS) — -8.8; -7.3; -9.1 Score on scale — p=0.89
Phase 2 N=155 Safety and Tolerability Study of NBI-98854 for the Treatment of Subjects With Tourette Syndrome
Tourette Syndrome
Primary: Frequency of Treatment-emergent Adverse Events (TEAEs) — 20; 29; 68 Participants
N/A N=12 Repetitive Transcranial Magnetic Stimulation to Reduce Tics
Tourette Syndrome
Primary: Yale Global Tic Severity Scale — 23.2; 21.7 units on a scale (0 - 50)
Phase 3 N=20 An Open-label Study to Determine the Efficacy and Safety of Topiramate in the Treatment of Tourette Syndrome.
Tourette Syndrome
Primary: Change in TTS — -14.29 units on a scale
N/A N=21 Proof of Concept Study of an Oral Orthotic to Reduce Tic Severity in Chronic Tic Disorder and Tourette Syndrome
Tourette Syndrome · Chronic Tic Disorder
Primary: Change in Global Severity of Tics and Clinical Condition as Measured by YGTSS — 20.19; 25.82 score on a scale
Phase 2 N=63 Pramipexole Pilot Phase II Study in Children and Adolescents With Tourette Disorder According to DSM-IV Criteria
Tourette Syndrome
Primary: Mean Change From Baseline in Total Tic Score of the Yale Global Tic Severity Scale — -7.17; -7.16 score on a scale — p=0.996
Phase 3 N=158 A Study to Test if TEV-50717 is Effective in Relieving Tics Associated With Tourette Syndrome (TS)
Tourette Syndrome
Primary: Change From Baseline in the TTS of the YGTSS at Week 8 Between High-Dose TEV-50717-Treated Participants and Placebo-Treated Participants — -7.8; -7.0 units on a scale…
Phase 4 N=30 Developing New Treatments for Tourette Syndrome: Therapeutic Trials With Modulators of Glutamatergic Neurotransmission
Tourette Syndrome
Primary: The Change From Baseline to 6-week Scores for The Total Tic Subscale (TTS) — 6.2; 10.5; 10.2 units on a scale
Phase 2 N=153 Ecopipam Tablets to Study Tourette's Syndrome in Children and Adolescents
Tourette Syndrome
Primary: Change From Baseline in the Yale Global Tic Severity Scale-Total Tic Score (YGTSS-TTS) at Week 12 — -9.87; -6.42 score on a scale — p==0.011
Phase 3 N=61 Aripiprazole in Children and Adolescents With Chronic Tic Disorder or Tourette's Disorder
Chronic Motor or Vocal Tic Disorder · Tourette's Disorder
Primary: Mean Change of Total Tic Scores in K-YGTSS From Randomization (Baseline, Visit 2) to the Final Visit (Visit 7) — -9.62; -14.97 units on a scale
Phase 2 N=124 Ecopipam Tablets to Study Tourette Syndrome in Children and Adolescents - Open Label Extension
Tourette Syndrome in Children · Tourette Syndrome in Adolescence
Primary: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) and Their Relationship (Unrelated, Possibly Related, or Probably Related) — 84; 2; 44…
N/A N=31 Open-label MNS for Tourette Syndrome
Tourette Syndrome · Tic Disorder, Chronic Motor or Vocal
Primary: Time Spent Using the Device Per Day of Use — 49.6 minutes per day
Phase 2 N=4 Proof-of-Concept Safety Study of CPP-109 (Vigabatrin) for Treatment Refractory Tourette's Disorder
Tourette's Disorder
Primary: Global Severity Score on the Y-GTSS — 80.25; 78.75; 61; 69.75 units on a scale
Phase 2 N=127 Safety, Tolerability, and Efficacy of NBI-98854 for the Treatment of Pediatric Subjects With Tourette Syndrome
Tourette Syndrome
Primary: Change From Baseline to Week 12 in the Yale Global Tic Severity Scale (YGTSS) Total Tic Score (TTS) — -6.8; -8.9 score on a scale — p=0.1768
Phase 3 N=110 Safety and Tolerability of Once-daily Oral Aripiprazole in Children and Adolescents With Tourette's Disorder
Tourette's Disorder · Tic Disorder
Primary: Percentage of Participants With Adverse Events. — 76.4; 4.5; 3.6 Percentage of participants
Phase 3 N=135 Efficacy & Safety Study of Once-weekly Oral Aripiprazole in Children and Adolescents With Tourette's Disorder
Tourette's Disorder
Primary: Change From Baseline in Yale Global Tic Severity Scale (YGTSS) - Total Tic Score (TTS) — -12.34; -7.72 score on a scale — p==0.0028
Phase 3 N=83 Efficacy & Safety Study of Once-weekly Oral Aripiprazole in Children and Adolescents With Tourette's Disorder (TD)
Tourette's Disorder
Primary: Mean Change From Baseline to Week 8 in Yale Global Tic Severity Scale (YGTSS) Total Tic Score — -8.2; -9.9; -14.5; -9.6 score on scale